What do we know about the serotonergic genetic heterogeneity in attention-deficit/hyperactivity and autistic disorders?

Psychopathology

Volumn 40, Issue 5, 2007, Pages 329-337

  Sinzig, J ^a,b   Lehmkuhl, G ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Attention deficit hyperactivity disorder; Autism; Pharmacogenetics; Serotonin

Indexed keywords

ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; PHARMACOGENETICS; SEROTONINERGIC SYSTEM;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; CHILD; CHROMOSOMES, HUMAN, PAIR 17; COMORBIDITY; GENOTYPE; HUMANS; MINISATELLITE REPEATS; PROMOTER REGIONS (GENETICS); SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 34547872349     PISSN: 02544962     EISSN: None     Source Type: Journal    
DOI: 10.1159/000105531     Document Type: Article

References (86)

1. Biedermann J, Newcorn J, Sprich S: Comorbidity of attention-deficit/ hyperactivity disorder with conduct, depressive anxiety and other disorders. Am J Psychiatry 1991;148:564-577.
2. Gillberg C: Asperger syndrome in 23 Swedish children. Dev Med Child Neurol 1989;31:520-531.
3. Jensen VK, Mack KK: Differential diagnosis between attention-deficit/ hyperactivity disorder and pervasive developmental disorder not otherwise specified. Clin Pediatr 1997;36:555-561.
4. Gadow KD, Devincent CJ, Pomeroy J: ADHD symptom subtypes in children with pervasive developmental disorder. J Autism Dev Disord 2006;14:1-13.
5. Clark T, Tinline C, Vostanis P: Autistic symptoms in children with attention-deficit/ hyperactivity disorder. Eur Child Adolesc Psychiatry 1999;8:50-55.
6. Yoshida Y, Uchiyama T: The clinical necessity for assessing attention-deficit/hyperactivity disorder symptoms in children with high-functioning pervasive developmental disorder. Eur Child Adolesc Psychiatry 2004;13:307-314.
7. Hattori J, Tatsuya O, Kiyoko A, Kousuke N, Makio O, Ohtsuka Y: Are pervasive developmental disorders and attention-deficit/hyperactivity disorder distinct disorders? Brain Dev 2006;28:371-374.
8. Holtmann M, Boelte S, Poustka F: ADHD, Asperger syndrome and high-functioning autism. J Am Acad Child Adolesc Psychiatry 2005;44:1101.
9. Fisher SE, Francks C, McCracken JT, McCough JJ, Marlow AJ, MacPhie IL, Newbury DF, Crawford LR, Palmer CG, Woodward JA, Del'Homme M, Cantwell DP, Nelson SF, Monaco AP, Smalley SL: A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. Am J Hum Genet 2002;70:1183-1196.
10. Spence SJ: The genetics of autism. Semin Pediatr Neurol 2004;11:196-204.
11. Smalley SL, Kustanovich V, Minassian SL, Stone JL, Ogdie MN, McCough JJ, McCracken JT, MacPhie IL, Francks C, Fisher SE, Cantor RM, Monaco AP, Nelson SF: Genetic linkage of attention-deficit/hyperactivity disorder on chromosome 16p13, in a region implicated in autism. Am J Hum Genet 2002;71:959-963.
12. Ogdie MN, Macphie IL, Minassian SL, Yang M, Fisher SE, Francks C, Cantor RM, McCracken JT, McGough JJ, Nelson SF, Monaco AP, Smalley SL: A genomewide scan for attention-deficit/hyperactivity disorder in an extended sample: suggestive linkage on 17p11. Am J Hum Genet 2003;72:1268-1279.
13. McCauley JL, Li C Jiang L, Olson LM, Crockett G, Gainer K, Folstein SE, Haines JL, Sutcliffe JS: Genome-wide and ordered-subset linkage analyses provide support for autism loci on 17q and 19p with evidence of phenotypic and interlocus genetic correlates. BMC Med Genet 2005;12:1.
14. Bakker SC, van der Meulen EM, Buitelaar JK, Sandkuijl LA, Pauls DL, Monsuur AJ, van't Slot R, Minderaa RB, Gunning WB, Pearson PL, Sinke RJ: A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. Am J Hum Genet 2003;72:1251-1260.
15. IMGSAC - Collaborative Linkage Study of Autism: An autosomal genomic screen for autism. Am J Med Genet 2001;8:609-615.
16. Comings DE, Gade-Andavolu R, Gonzalez N, Wu S, Muhleman D, Blake H, Chiu F, Wang E, Farwell K, Darakjy S, Baker R, Dietz G, Saucier G, MacMurray JP: Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder. Clin Gen 2000;58:31-40.
17. Comings DE, Gade-Andavolu R, Gonzalez N, Blake H, Wu S, MacMurray JP: Additive effect of three noradrenergic genes (ADRA2a, ADRA2c, DBH) on attention-deficit/hyperactivity disorder and learning disabilities in Tourette syndrome subjects. Clin Genet 1999;55:160-172.
18. Barr CL, Kroft J, Feng Y, Wigg K, Roberts W, Malone M, Ickowicz A, Schachar R, Tannock R, Kennedy JL: The norepinephrine transporter gene and attention-deficit/hyperactivity disorder? Am J Med Genet 2002;114:255-259.
19. Roman T, Schmitz M, Polanczyk GV, Eizirik M, Rhode LA, Hutz MH: Is the α-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? Am J Med Genet B Neuropsychiatr Genet 2003;120:116-120.
20. De Luca V, Muglia P, Vincent JB, Lanktree M, Jain U, Kennedy JL: Adrenergic α-2C receptor genomic organization: association study in adult ADHD. Am J Med Genet B Neuropsychiatr Genet 2004;127:65-67.
21. De Luca V, Muglia P, Jain U, Kennedy JL: No evidence of linkage between the norepinephrine transporter gene MnII polymorphism and adult ADHD. Am J Med Genet B Neuropsychiatr Genet 2004;124:38-40.
22. Bobb AJ, Addington AM, Sidransky E, Gornick, MC, Lerch JP, Greenstein DK, Clasen LS, Sharp WS, Inoff-Germain G, Wavrant-De Vrieze F, Arcos-Burgos M, Straub RE, Hardy JA, Castellanos FX, Rapoport JL: Supports for the association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet 2005;134:67-72.
23. Thapar A: attention-deficit/hyperactivity disorder: unravelling the molecular genetics. Mol Psychiatry 1998;3:370-372.
24. Ruotsalainen S, Sirvio J, Jakala P, Puumala T, MacDonald E, Riekkinen P Sr: Differential effects of three 5-HT receptor antagonists on the performance of rats in attentional and working memory tasks. Eur Neuropharmacol 1997;7:99-108.
25. Puumala T, Sirvio J: Changes in activities of dopamine and serotonin systems in the frontal cortex underlie poor choice accuracy and impulsivity of rats in an attention task. Neuroscience 1998;83:489-499.
26. Giros B, Jaber, M, Jones SR, Wightman RM, Caron MG: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;379:606-612.
27. Gainetdinov R, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG: Role of serotonin in the paradoxical calming effect of psycho-stimulants on hyperactivity. Science 1999;283:397-401.
28. Murphy DL, Lerner A, Rudnick G, Lesch KP: Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv 2004;4:109-123.
29. Manor I, Eisenberg J, Tyano S, Sever Y, Cohen H, Ebstein R, Kotler M: Family- based association study of the serotonin transporter promoter region polymorphism (5-HTTLPR) in attention-deficit/hyperactivity disorder. Am J Med Genet Neuropsychiatr Genet 2001;105:91-95.
30. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531.
31. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-2624.
32. Greenberg BD, Tolliver TJ, Huang SJ, et al: Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 1989;88:83-87.
33. Hanna GL, Himle JA, Curtis GC, Koram DQ, Veenstra-VanderWeele J, Leventhal BL, Cook EH Jr: Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology 1998;18:102-111.
34. McKenzie A, Quinn J: A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci USA 1999;96:15251-15255.
35. Battersby S, Ogilvic A, Blaxkwood DHR, Shen S, Muqit MMK, Muir WI, Teague P, Goodwin GM, Harmar AJ: Presence of multiple functional polyadenylation signals and single nucleotide polymorphism in the 3′ untranslated region of the human serotonin transporter gene. J Neurochem 1999;72:1384-1388.
36. Seeger G, Schloss P, Schmidt MH: Functional polymorphism within the promoter of the serotonin transporter is associated with severe hyperkinetic disorders. Mol Psychiatry 2001;6:235-238.
37. Kent L, Doerry U, Hardy E, Parmar R, Gingell K, Hawi Z, Kiney A, Lowe N, Fitzgerald M, Gill M, Craddock M: Evidence that variation at the serotonin transporter gene influences susceptibility to attention-deficit/hyperactivity disorder: analysis and pooled analysis. Mol Psychiatry 2002;7:908-912.
38. Zoroglu SS, Erdal ME, Alasehirli B, Erdal N, Sivasli E, Tutkun H, Savas HA, Herken H: Significance of serotonin transporter gene 5-HTTLPR and variable number of tandem repeat polymorphism in attention deficit hyperactivity disorder. Neuropsychobiology 2002;45:176-181.
39. Langley K, Payton A, Hamshere ML, Pay HM, Lawson DC, Turic D, Ollier W, Worthington J, Owen MJ, O'Donovan MC, Thapar A: No evidence of association of two 5-HT transporter gene polymorphisms and attention-deficit/hyperactivity disorder. Psychiatr Genet 2003;13:107-110.
40. Curran S, Purcell S, Craig I, Asherson P, Sham P: The serotonin transporter gene as a QTL for ADHD. Am J Med Genet B Neuropsychiatr Genet 2005;134:42-47.
41. Retz W, Retz-Junginger P, Supprian T, Thome J, Rösler M: Association of serotonin transporter promoter gene polymorphism with violence: relation with personality disorders, impulsivity and childhood ADHD psychopathology. Behav Sci Law 2004;22:415-425.
42. Anderson GM, Freedman DX, Cohen DJ, Volkmar FR, Hoder EL, McPhedran P, Minderaa B, Hansen CR, Young JG: Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry 1987;28:885-900.
43. Abramson RK, Wright HH, Carpenter R, Brennan W, Lumpuy O, Cole E, Young SR: Elevated blood serotonin in autistic probands and their first-degree relatives. J Autism Dev Disord 1989;19:397-407.
44. Marazitti D, Muratori F, Cesari A, Masal I, Baroni S, Giannacinni G, Dell'Osso L, Cosenza A, Pfanner P, Cassana GB: Increased density of the platelet serotonin transporter in autism. Pharmacopsychiatry 2000;33:165-168.
45. Cook EH, Courchesne R, Lord C, Cox NJ, Yan S, Lincoln A, Haas R, Courchesne E, Leventhal BL: Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry 1997;2:247-250.
46. Klauck SM, Poustka F, Benner A, Lesch KP, Poustka A: Serotonin transporter (5-HTT) gene variants associated with autism? Hum Mol Genet 1997;6:2233-2238.
47. Kim SJ, Cox N, Courchesne R, Lord C, Corsello C, Akshoomoff N, Guter S, Leventhal BL, Courchesne E, Cook EH Jr: Transmission disequilibrium mapping in the serotonin transporter gene (SLC6A4) region in autistic disorder. Mol Psychiatry 2002;7:278-288.
48. Conroy J, Meally E, Kearney G, Fitzgerald M, Gill M, Gallgher L: The serotonin transporter gene and autism: a haplotype analysis in an Irish autistic population. Mol Psychiatry 2004;9:587-593.
49. McCauley JL, Olson LM, Dowd M, Amin T, Steele A, Blakely RD, et al: Linkage and association analysis at the serotonin transporter (SLC6A4) locus in a rigid-compulsive subset of autism. Am J Med Genet B Neuropsychiatr Genet 2003;105:381-386.
50. Maestrini E, Lai C, Marlow A, Matthews N, Wallace S, Bailey A, Cook EH, Weeks DE, Monaco AP: Serotonin transporter (5-HTT) and γ-aminobutyric acid receptor subunit β3 (GABRB3) gene polymorphisms are not associated with autism in the IMGSAC families. Am J Med Genet 1999;88:492-496.
51. Persico AM, Psacucci T, Pugliesi-Allegra S, Militerni R, Bravaccio C, Schneider C, et al: Serotonin transporter promoter variants do not explain the hyperserotonemia in autistic patients. Mol Psychiatry 2002;7:795-800.
52. Coutinho AM, Oliveira G, Morgadinho T, Fesel C, Macedo TR, Bento C, Marques C, Ataide A, Miguel T, Borges L, Vicente AM: Variants of the serotonin transporter gene (SLC6A4) significantly contribute to hyperserotonemia in autism. Mol Psychiatry 2004;9:264-271.
53. Betancur C, Corbex M, Spielewoy C, Philippe A, Laplanche JL, Launay JM, Gillberg C, Mouren-Simeoni MC, Hamon M, Giros B, Nosten-Bertrand M, Leboyer M: Serotonin transporter gene polymorphisms and hyperserotonemia in autistic children. Mol Psychiatry 2002;7:67-71.
54. Anderson GM, Gutknecht L, Cohen DJ, Braily-Trabard S, Cohen JH, Ferrari P, Roubertoux PL, Tordjman S: Serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia. Mol Psychiatry 2002;7:831-836.
55. Persico AM, Militerni R, Bravaccio C, Schneider C, Melmed R, Conciatori M, Melmed R, Trillo S, Montecchi F, Palermo M, Rabinowitz D, Reichelt KL, Conciatori M, Marino R, Keller F: Lack of association between serotonin transporter gene promoter variants and autistic disorder in two ethnically distinct samples. Am J Med Genet 2000;96:123-127.
56. Ozaki N, Goldman D, Kaye WH, Plotnicov K, Greenberg BD, Lappalainen J, Rudnick G, Murphy DL: Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry 2003;8:933-936.
57. Coon H, Dunn D, Lainhart J, Miller J, Hamil C, Battaglia A, Tancredi R, Leppert MF, Weiss R, McMahon W: Related Articles, Possible association between autism and variants in the brain-expressed tryptophan hydroxylase gene (TPH2). Am J Med Genet B Neuropsychiatr Genet 2005;135:42-46.
58. Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M: Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 1991;30:762-767.
59. Hedges D, Reimherr FW, Rogers A, Strong R, Wender PH: An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull 1995;31:779-783.
60. Adler LA, Resnick S, Kunz M, Devinskiy O: Open-label trial of venlafaxine in adult patients with attention deficit-/hyperactivity disorder. Psychopharmacol Bull 1995;31:785-788.
61. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ: Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114:1-8.
62. Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D: Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005;44:240-248.
63. Aman MG, Lam KS, Van Bourgondien ME: Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 2005;15:116-126.
64. Birmaher B, Quintana H, Greenhill LL: Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry 1988;27:248-251.
65. Strayhorn JM, Rapp N, Donina W, Strain PS: Randomized trial of methylphenidate for an autistic child. J Am Acad Child Adolesc Psychiatry 1988;27:244-247.
66. Handen BL, Johnson CR, Lubetsky M: Efficacy of methylphenidate among children with autism and symptoms of attention-deficit/ hyperactivity disorder. J Autism Dev Disord 2000;30:245-255.
67. Di Martino A, Melis G, Cianchetti C, Zuddas A: Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol 2004;14:207-218.
68. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar RA: Placebo-controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005;30:582-589.
69. Moore ML, Eichner SF, Jones JR: Treating functional impairment of autism with selective serotonin-reuptake inhibitors. Ann Pharmacother 2004;38:1515-1519.
70. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ: Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997;36:685-693.
71. Nicolson R, Awad G, Sloman L: An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998;37:372-376.
72. Rhode LA, Roman T, Hutz MH: Attention-deficit/ hyperactivity disorder: current aspects on pharmacogenetics. Pharmacogenomics J 2003;3:11-13.
73. Rhode LA, Roman T, Szobot C, Cunh RD, Hutz M, Biedermann J: Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/ hyperactivity disorder: a pilot study. Synapse 2003;48:87-89.
74. Hamarman S, Fossella J, Ulger C, Brimacombe M, Dermody J: Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention-deficit/hyperactivity disorder: a pharmacogenetic study. J Child Adolesc Psychopharmacol 2004;14:564-574.
75. Seeger G, Schloss P, Schmidt MH: Marker gene polymorphism in hyperkinetic disorder - predictors of clinical response to treatment with methylphenidate? Neuroscience Letter 2001;313:45-48.
76. Veenstra-VanderWeele J, Anderson GM, Cook EH Jr: Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 2000;27:165-181.
77. Palermo MT, Curatolo P: Pharmacologic treatment of autism. J Child Neurol 2004;19:155-164.
78. Brown CS, Kent TA, Bryant SG, Gevedon RM, Campbell JL, Felthous AR, Barratt ES, Rose RM: Blood platelet uptake of serotonin in episodic aggression. Psychiatry Res 1989;27:5-12.
79. Cook EH Jr, Stein MA, Ellison T, Unis AS, Leventhal BL: Attention-deficit/hyperactivity disorder and whole-blood serotonin levels: effects of comorbidity. Psychiatry Res 1995;57:13-20.
80. Spivak B, Vered Y, Yoran-Hegesh R, Averbuch E, Mester R, Graf E, Weizman A: Circulatory levels of catecholamines, serotonin and lipids in attention-deficit/hyperactivity disorder. Acta Psychiatr Scand 1999;99:300-304.
81. Halperin JM, Newcorn JH, Kopstein I, McKay KE, Schwartz ST, Siever LJ, Sharma V: Serotonin, aggression, and parental psychopathology in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36:1391-1398.
82. Donovan AM, Halperin JM, Newcorn JH, Sharma V: Thermal response to serotonergic challenge and aggression in attention deficit hyperactivity disorder children. J Child Adolesc Psychopharmacol 1999;9:85-91.
83. Gillberg IC, Gillberg C, Rastam M, Johansson M: The cognitive profile of anorexia nervosa: a comparative study including a community-based sample. Compr Psychiatry 1996;37:23-30.
84. Matsushita S, Suzuki K, Murayama M, Nishiguchi N, Hishimoto A, Takeda A, Shirakawa O, Higuchi S: Serotonin transporter regulatory region polymorphism is associated with anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet 2004;128:114-117.
85. Kaye WH, Frank GK, Bailer UF, Henry SE, Meltzer CC, Price JC, Mathis CA, Wagner A: Serotonin alterations in anorexia nervosa and bulimia nervosa: new insights from imaging studies. Int J Physiol Behav 2005;85:73-81.
86. Sutcliffe JS, Delahanty RJ, Prasad HC, McCauley JL, Han Q, Jiang L, Li C, Folstein SE, Blakely RD: Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet 2005;77:265-279.